High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patients

Journal of Biological Regulators and Homeostatic Agents

Volumn 27, Issue 3, 2013, Pages 903-908

  Saraceno, Rosita ^a   Rizza, S ^a   Faleri, S ^a   Federici, M ^a   Nistico S P ^a   Copetti, M ^b   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Infliximab; Long term treatment; Predictors; Psoriasis; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; LIPID METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BLOOD; DRUG ANTAGONISM; LETTER; MIDDLE AGED; STATISTICAL MODEL; ANTAGONISTS AND INHIBITORS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHOLESTEROL, HDL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891592352     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496-509.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-28.
3. Chiricozzi A, Zhang S, Dattola A, Gabellini M, Chimenti S, Nisticò SP. Role of Th17 in the pathogenesis of cutaneous inflammatory diseases. J Biol Regul Homeost Agents 2012; 26(3):313-8.
4. Chiricozzi A, Zhang S, Dattola A, Cannizzaro MV, Gabellini M, Chimenti S, Nisticò SP. New insights into the pathogenesis of cutaneous autoimmune disorders. J Biol Regul Homeost Agents 2012; 26(2):165-70.
5. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005:273-9.
6. Saraceno R, Gottlieb AB. Infliximab in the treatment of plaque psoriasis: a review article. Therapy 2007; 4:399-406.
7. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
8. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367-74.
9. Papoutsaki M, Talamonti M, Giunta A, Costanzo A, Ruzzetti M, Teoli M, Chimenti S. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010; 221(S)1:43-7.
10. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12:R94.
11. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69:2002-8.
12. Marotte H, Miossec P. Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. Joint Bone Spine 2010;77:297-305.
13. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119:1135-45.
14. de la Llera Moya M, McGillicuddy FC, Hinkle CC, et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012; 222:390-4.
15. Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012; 224:218-21.
16. Cheng AM, Handa P, Tateya S, et al. Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One 2012; 7:e33917.
17. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009; 22:61-73.